Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes

被引：2

作者：

Mak K.H. ^{[1
]}

Moliterno D.J. ^{[1
]}

机构：

[1] Department of Cardiology, F-25, Cleveland Clinic Foundation, Cleveland, OH 44195

来源：

Current Cardiology Reports | 1999年 / 1卷 / 3期

关键词：

Acute Coronary Syndrome; Unstable Angina; Abciximab; Eptifibatide; Tirofiban;

D O I：

10.1007/s11886-999-0023-y

中图分类号：

学科分类号：

摘要：

Acute coronary syndromes are a leading cause of hospitalization in industrialized countries. Current antithrombotic therapy focuses on relatively weak antiplatelet agents and heparin. The advent of inhibitors of the platelet glycoprotein IIb/IIIa receptor, the final common pathway for aggregation, provides a new therapeutic modality. Clinical trials with a total of more than 18,000 patients have clearly shown the benefits of intravenous IIb/IIIa blockade. Overall, at 30 days, 13 fewer deaths or myocardial infarctions occurred for every 1000 patients treated in these trials. This favorable outcome was extended to 6 months, resulting in 16 fewer such events per 1000 patients treated. Importantly, these benefits were not accompanied by an excessive occurrence in bleeding complications or thromb-ocytopenia. To further improve outcomes in this high-risk group of patients, strategies pertaining to prolonged periods of vessel passivation with oral formulations and early or delayed invasive approaches are being studied. Copyright © 1999 by Current Science Inc.

引用

页码：199 / 205

页数：6

共 28 条

[1]

Theroux P., Ouimet H., McCans J., Et al., Aspirin, heparin, or both to treat acute unstable angina, N Engl J Med, 319, pp. 1105-1111, (1988)

[2]

Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease, Lancet, 336, pp. 827-830, (1990)

[3]

Lewis Jr. H.D., Davis J.W., Archibald D.G., Et al., Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study, N Engl J Med, 309, pp. 396-403, (1983)

[4]

Cairns J.A., Gent M., Singer J., Et al., Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial, N Engl J Med, 313, pp. 1369-1375, (1985)

[5]

Cohen M., Adams P.C., Parry G., Et al., Combination antithrombotic therapy in unstable rest angina and non-Q-wave myocardial infarction in nonprior aspirin users, Circulation, 89, pp. 81-88, (1994)

[6]

Oler S., Whooley M.A., Oler J., Grady D., Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina, JAMA, 276, pp. 811-815, (1996)

[7]

Vetrovec G.W., Cowley M.J., Overton H., Richardson D.W., Intracoronary thrombus in syndromes of unstable myocardial ischemia, Am Heart J, 102, pp. 1202-1208, (1981)

[8]

Capone G., Wolf N.M., Meyer B., Meister S.G., Frequency of intracoronary filling defects by angiography in angina pectoris at rest, Am J Cardiol, 56, pp. 403-406, (1985)

[9]

Freeman M.R., Williams A.E., Chisholm R.J., Armstrong P.W., Intracoronary thrombus and complex morphology in unstable angina, Circulation, 80, pp. 17-23, (1989)

[10]

Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: Results of the TIMI IIIB trial, Circulation, 89, pp. 1545-1556, (1994)

← 1 2 3 →